CLEBOPRIDE MALEATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H24ClN3O2.C4H4O4
Molecular Weight	489.949
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)\C=C/C(O)=O.COC1=C(C=C(Cl)C(N)=C1)C(=O)NC2CCN(CC3=CC=CC=C3)CC2

InChI

InChIKey=BCVIWCRZYPHHMQ-BTJKTKAUSA-N

InChI=1S/C20H24ClN3O2.C4H4O4/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14;5-3(6)1-2-4(7)8/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25);1-2H,(H,5,6)(H,7,8)/b;2-1-

HIDE SMILES / InChI

Molecular Formula	C20H24ClN3O2
Molecular Weight	373.876
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C4H4O4
Molecular Weight	116.0722
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://onlinelibrary.wiley.com/doi/10.1002/9781118541203.xen306/abstract

Clebopride is a dopamine antagonist drug. It is used to treat functional gastrointestinal disorder such as nausea or vomiting. Unchanged parent drug was the most abundant compound in human urine. Major metabolites included the hydroxylation at benzyl group to yield carbinolamine and its further N-dealkylation product, and the piperidine ring hydroxylation/oxidation metabolite (a lactam).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277	Antagonist 2778		2.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Vomiting 38 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14871277 https://www.drugs.com/international/clebopride.html	Primary		Approved 8429	CLEBOPRIDE Approved Use Clebopride is used in the treatment of stomach ulcer, inflammation of stomach and intestine, indigestion. It also reduces the symptoms like excessive air accumulation in gut, nausea and vomiting associated with stomach discomfort.

PubMed

Title	Date	PubMed
[Drug-induced extrapyramidal syndrome. Apropos of 22 cases].	1987 Feb	3565961
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.	1993 Jun 11	8359205
Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers.	2002	12453314
Dopamine antagonists during parturition disrupt maternal care and the retention of maternal behavior in rats.	2002 Nov	12213533
[Rabbit syndrome due to clebopride].	2003 Jun 7	12812712
Stereocontrolled dopamine receptor binding and subtype selectivity of clebopride analogues synthesized from aspartic acid.	2003 Oct 6	12951112
Progressive supranuclear palsy syndrome induced by clebopride.	2004 Apr	15077251
Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics.	2004 Feb 15	14871277
Etiological and therapeutical observations in a case of belly dancer's dyskinesia.	2005 Feb	15455446
Etiological and therapeutical observations in a case of belly dancer's dyskinesia.	2006 Sep	16830316
Prokinetic drug utility in the treatment of gastroesophageal reflux esophagitis: a systematic review of randomized controlled trials.	2007	21673949
Effect of clebopride, antidopaminergic gastrointestinal prokinetics, on cardiac repolarization.	2007 Jan-Feb	17365143
Development and validation of a LC-MS/MS method for the determination of clebopride and its application to a pharmacokinetics study in healthy Chinese volunteers.	2010 Aug 1	20598654
A randomized, controlled, double-blind trial of the adjunct use of Clebopride in polyethylene glycol electrolyte (PEG) solution for colonoscopy preparation.	2010 Jan	20305329
[A new method of investigation of "child's" behavior (infant-mother attachment) of newborn rats].	2010 Mar-Apr	20469600
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2.	2011 Jul 14	21599003

Patents

Sample Use Guides

In Vivo Use Guide

500 mcg 3 times/day.

Route of Administration: Oral

In Vitro Use Guide

Clebopride at 10 uM significantly decreased the Vmax of phase 0 depolarization in isolated rabbit Purkinje fiber and significantly prolonged the action potential duration at 90% repolarization, whereas the action potential duration at 50% repolarization was not prolonged. For hERG potassium channel currents in human ether-à-go-go-related gene (hERG)-stably transfected Chinese hamster ovarian (CHO) cells the IC50 value was 0.62 uM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:59:10 GMT 2023` Edited by `admin` on `Fri Dec 15 16:59:10 GMT 2023`
Record UNII	P42041X5SU
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CLEBOPRIDE MALEATE

Common Name

English

4-(4-AMINO-5-CHLORO-2-METHOXYBENZAMIDO)-1-BENZYLPIPERIDINE MALEATE SALT

Common Name

English

CLEBOPRIDE MALEATE SALT

Common Name

English

CLEBOPRIDE HYDROGEN MALEATE

Common Name

English

Code System Code Type Description

EVMPD

SUB01334MIG